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Abstract
Background: The percentage of women giving birth after the age of 35 increased in many western
countries. The number of women remaining childless also increased, mostly due to aging oocytes.
The method of oocyte donation offers the possibility for infertile older women to become
pregnant. Gestation after oocyte-donation-IVF, however, is not without risks for the mother,
especially at advanced age.
Case presentation: An infertile woman went abroad for oocyte-donation-IVF, since this
treatment is not offered in The Netherlands after the age of 45. The first oocyte donation
treatment resulted in multiple gestation, but was ended by induced abortion: the woman could not
cope with the idea of being pregnant with twins. During the second pregnancy after oocyte
donation, at the age of 50, she was mentally more stable. The pregnancy, again a multiple gestation,
was uneventful until delivery. Immediately after delivery the woman had hypertension with nausea
and vomiting. A few hours later she had an eclamptic fit. HELLP-syndrome was diagnosed. She died
due to cerebral haemorrhage.
Conclusion: In The Netherlands, the age limit for women receiving donor oocytes is 45 years and
commercial oocyte donation is forbidden by law. In other countries there is no age limit, the reason
why some women are going abroad to receive the treatment of their choice.
Advanced age, IVF and twin pregnancy are all risk factors for pre-eclampsia, the leading cause of
maternal death in The Netherlands.
Patient autonomy is an important ethical principle, but doctors are also bound to the principle of 
'not doing harm', and do have the right to refuse medical treatment such as IVF-treatment. The 
discussion whether women above 50 should have children is still not closed. If the decision is made 
to offer this treatment to a woman at advanced age, the doctor should counsel her intensively 
about the risks before treatment is started.
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Background
In the Netherlands the proportion of women giving birth
after the age of 35 increased from 5.2% in 1980 to 20% in
2003 [1]. This has also been reported in other countries
[2].
The number of women remaining childless also increased,
mostly due to aging oocytes [3]. The method of oocyte
donation from younger women and in vitro fertilization
(IVF), offers the possibility for infertile older women to
become pregnant. However, this is not without risks for
the mother [4].
In The Netherlands, the age limit for women receiving
donor oocytes is 45 years [5]. In many other countries the
maximum age is higher and sometimes even without lim-
its. Also, in The Netherlands, commercial oocyte donation
is forbidden by law (so called embryo law, implemented
in 2002), therefore, some women are going abroad to
receive the treatment of their choice.
In this short communication we present a case of mater-
nal death, illustrating that the application of new technol-
ogies of assisted reproduction in high income countries
creates a new group of women at risk of maternal death.
Case presentation
The woman got pregnant for the first time at the age of 36
but had a miscarriage twice. When she was 38 years old,
she had two induced abortions. At the age of 41 and 43
years, she got pregnant after ovulation induction, and
gave birth to a healthy girl and boy respectively. After this,
she suffered from secondary subfertility, but ovulation
induction did not result in pregnancy. At the age of 46,
after oocyte donation embryotransfer was performed
abroad, resulting in a twin pregnancy. However, the
woman could not live with the idea of carrying twins. She
first opted for termination of pregnancy, but then agreed
with selective foeticide in the same clinic. She could still
not cope with the pregnancy and opted for abortion of the
second twin in the second trimester.
At the age of 49 she again had oocyte donation and IVF in
another clinic abroad, resulting in a twin pregnancy. She
now seemed to be mentally more stable. Antenatal visits
were at a Dutch clinic, and the pregnancy developed une-
ventful. At a gestational age of 37 weeks her blood pres-
sure had risen from 110/60 to 125/80 mmHg. At 38 weeks
labour was induced for elective reasons and the woman
delivered a healthy boy and girl, at the age of 50. Shortly
after delivery her blood pressure had risen to 170/100
mmHg. She complained of nausea and vomiting. No
diagnostic tests, however, were performed and no antihy-
pertensive or anticonvulsant therapy was initiated. Nine
hours later she was found unconscious in bed with a
tongue bite. Magnesium sulfate was initiated, but she had
two more convulsions. Blood results showed signs of
HELLP-syndrome. Following the eclamptic fit she was
somnolent and disoriented, with a blood pressure of 140/
85 mmHg. After 24 hours the CT-scan showed occipital
haemorrhage and cerebral oedema. The woman was
transferred to the Intensive Care Unit. After a few hours
the Glasgow Coma Scale deteriorated and a midline shift
was visible on the CT scan. Treatment was stopped
because of brain death. Her husband was left behind with
four children.
Discussion
This woman died from eclampsia, after she had a multiple
pregnancy at advanced age after oocyte donation IVF. She
insisted to have this treatment and being denied IVF in her
own country, The Netherlands, she had it performed
abroad. The woman had hypertension and pre-eclamptic
complaints, but was not managed with antihypertensive
medication or magnesium sulphate.
We feel that even the first oocyte donation for this woman
could be criticised, but are astonished that doctors did
institute such rigorous treatment for the second time, at
the age of 49, after the first pregnancy resulting from
oocyte donation was chosen to be terminated. The availa-
bility of advanced reproductive technology, especially for
the wealthier women in society, may create a new, unnec-
essary group at risk for severe maternal morbidity and
mortality in high income countries. Women should be
counselled intensively about the risks involved.
IVF, twin pregnancy and advanced age are all risk factors
for pre-eclampsia, one of the five major causes of maternal
death worldwide, and the leading cause of maternal mor-
tality in The Netherlands.
IVF-pregnancies are associated with more obstetric com-
plications than naturally conceived pregnancies [6]. Käl-
lén et al found higher risks of pre-eclampsia (OR 1.63;
95% CI 1.53–1.74), placental abruption (OR 2.17; 95%
CI 1.74–2.72) and postpartum haemorrhage (OR 1.4; 9%
CI 1.38–1.50) in women being pregnant after IVF-treat-
ment [7]. Venn et al reported an increased risk of maternal
mortality in IVF pregnancies: 25.7 per 100.000 pregnan-
cies compared to 10.9 in non-IVF pregnancies [8].
Whether oocyte donation adds an additional risk to the
higher risks of obstetric complications in IVF-pregnancies
remains controversial, but most studies indicate an addi-
tional risk. Söderström-Anttila et al compared obstetric
outcome of pregnancy after oocyte donation with preg-
nancies after standard IVF. In singleton pregnancies they
observed 29% (12/41) pregnancy-induced hypertension
in the first group versus 12% (8/68) in the other group (PReproductive Health 2008, 5:12 http://www.reproductive-health-journal.com/content/5/1/12
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< 0.05). Also, the caesarean section rate was higher: 57%
(29/51) in the group with oocyte donation versus 37%
(36/97) in the standard IVF group [9].
Henne et al found an increased risk of preterm labour,
pre-eclampsia and caesarean delivery (after controlling for
age and multiple gestations) in recipients of donor
oocytes versus women of advanced age with autologous
oocytes [10]. Wiggins et al found 26% (6/23) pregnancy-
induced hypertension in the group with donor egg IVF as
compared to 8% (1/12) in the group with standard IVF.
For nulliparous women this difference was even more sig-
nificant with 37% (13/35) in the donor egg IVF group and
8% (3/37) in the group with standard IVF (OR 7.1; 95%
CI 1.4–36.7) [11]. Sauer et al reported in their cohort
study in 37.8% (28/74) of pregnancies after oocyte dona-
tion obstetrical complications [12]. This was also seen in
the cohort of Abdalla, with a high risk of pregnancy
induced hypertension and postpartum haemorrhage [13].
Krieg et al compared 71 donor oocyte pregnancies with
108 IVF pregnancies using autologous oocytes at
advanced maternal age. They found no differences in inci-
dence of hypertensive disorders, gestational diabetes or
mode of delivery after controlling for multifetal gestation,
gestational age at delivery and maternal age [14].
Women being pregnant at advanced age have an increased
risk for pre-eclampsia and gestational diabetes [15].
Advanced age is also an independent risk factor for caesar-
ean delivery (OR 2.3, 95% CI 1.1–4.8) [16]. Paulson et al
reported an incidence of pre-eclampsia of 25% (10/40),
being 60% (6/10) in women older than 55 years. The inci-
dence of gestational diabetes was 17.5% (7/40), with an
incidence of 40% in women older than 55 years (4/10)
[17]. Doctors offering IVF procedures should be aware of
the risks named above.
Patient autonomy is an important ethical principle in
management, but we feel that there are limits to this. Doc-
tors are also bound to the principle of 'not doing harm'
and this principle was at stake in our case [18]. The discus-
sion whether women over the age of 50 should have chil-
dren is still not closed [2,3]. Landau even reports an
increase, rather than a decrease, of human suffering due to
the promise of post-menopausal pregnancy with unlim-
ited fertility [19]. Doctors do have the right to refuse to
give medical treatment such as IVF-treatment. If it is
decided to offer this treatment to a woman at advanced
age, she should be counseled intensively about the risks
before such treatment is started.
Conclusion
The discussion whether women at advanced maternal age
should become pregnant is still not closed. Doctors, how-
ever, have the right to refuse to perform such treatment.
Pregnancies at advanced maternal age after oocyte IVF-
treatment have increased risks of obstetrical complica-
tions. We should be aware of these risks and counsel
patients accordingly.
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